Bae Jang-Ho, Bassenge Eberhard, Lim Dong-Mee, Synn Yi-Chul, Kim Ki-Young, Schwemmer Michael
Division of Cardiology, College of Medicine, Konyang University Hospital, Gasoowon-dong, Seo-gu, Daejeon, South Korea.
Int J Cardiol. 2005 Jun 8;101(3):377-83. doi: 10.1016/j.ijcard.2004.03.046.
To evaluate the effects of the calcium channel blocker lacidipine on vascular responses, such as endothelial function and carotid intima-media thickness (IMT), and on levels of high-sensitivity C-reactive protein (hs-CRP) in patients with coronary artery disease (CAD).
Endothelial function was assessed by measuring the flow-mediated vasodilation (FMD) of the brachial artery and IMT was measured in the common, bifurcating, and in the internal carotid artery by using high-resolution ultrasound. The study population consisted of 96 consecutive patients [mean age 60 years, male (n) = 70] who showed at least one coronary artery narrowed by more than 50% (coronary angiography). These patients were randomly assigned to lacidipine treatment (4 mg/day, n = 48) or to a placebo (n = 48). We measured FMD, IMT, and hs-CRP prior to and after 6 months of treatment and following coronary angiography in all patients.
Clinical and medical history revealed no significant differences between the groups. IMT of the common carotid artery was significantly diminished from 0.92 +/- 0.15 to 0.87 +/- 0.15 mm 6 months after treatment with lacidipine (p < 0.005). However, IMT of any region in the carotid artery did not show any significant changes in the placebo group. Endothelial function and hs-CRP levels were slightly improved (insignificant) in the lacidipine group. In the placebo group, there were no significant changes.
Lacidipine leads to a significant reduction of the common carotid artery IMT as well as to a decrease in markers of inflammation in patients with CAD during a relatively short period (6 months).
评估钙通道阻滞剂拉西地平对冠状动脉疾病（CAD）患者血管反应（如内皮功能和颈动脉内膜中层厚度（IMT））以及高敏C反应蛋白（hs-CRP）水平的影响。
通过测量肱动脉的血流介导的血管舒张（FMD）评估内皮功能，并使用高分辨率超声测量颈总动脉、分叉处和颈内动脉的IMT。研究人群包括96例连续患者[平均年龄60岁，男性（n）=70]，这些患者至少有一条冠状动脉狭窄超过50%（冠状动脉造影）。这些患者被随机分配接受拉西地平治疗（4毫克/天，n = 48）或安慰剂治疗（n = 48）。我们在所有患者治疗6个月之前和之后以及冠状动脉造影后测量FMD、IMT和hs-CRP。
临床和病史显示两组之间无显著差异。拉西地平治疗6个月后，颈总动脉的IMT从0.92±0.15毫米显著降至0.87±0.15毫米（p < 0.005）。然而，安慰剂组颈动脉任何区域的IMT均未显示任何显著变化。拉西地平组的内皮功能和hs-CRP水平略有改善（不显著）。在安慰剂组中，没有显著变化。
在相对较短的时间（6个月）内，拉西地平可使CAD患者的颈总动脉IMT显著降低，并使炎症标志物减少。
